Prospective comparative assessment of liver stiffness and steatosis between iLivTouch and FibroScan.
4 affiliations
- 1Translational Research Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
- 2Gastroenterology and Obesity Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
- 3Integral Diagnosis and Treatment Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
- 4Hepatology and Transplants Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
Abstract
Background
Metabolic dysfunction-associated steatotic liver disease currently represents the leading cause of chronic liver disease worldwide. FibroScan and iLivTouch are 2 devices that employ similar principles to estimate liver steatosis and fibrosis, although few studies have directly compared their results.Aim
To evaluate the concordance of 2 transient elastography devices for the estimation of liver steatosis and fibrosis.Methods
A prospective study was conducted. Each participant underwent liver elastography with both devices consecutively under standardized conditions. Clinical, anthropometric, and biochemical variables were collected. The diagnostic accuracy of iLivTouch was calculated using FibroScan and noninvasive scores as references.Results
A total of 1004 patients were enrolled, with a median body mass index of 25.7 kg/m2 [IQR=23.6-28.7]. Median of attenuation values was 250 dB/m [IQR=214-291] with FibroScan, 262 dB/m [IQR=239-310] with iLivTouch. Median liver stiffness measurements were 4.1 kPa [IQR=3.4-4.8] for FibroScan and 6.2 kPa [IQR=5.5-7.1] for iLivTouch. Bland-Altman analysis revealed mean differences of -19.45±49.62 dB/m for steatosis and -2.43±2.51 kPa for stiffness. Using FibroScan (>269 dB/m) as the reference, iLivTouch ≥244 dB/m demonstrated 90% sensitivity for detecting liver steatosis. The correlation between the FAST scores of the 2 devices was very strong (rho=0.90, p≤0.0001).Conclusion
iLivTouch serves as an effective alternative to assess liver fibrosis and steatosis in the general population, including overweight and obese individuals.
Related
- Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study.
- Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with MASLD and type 2 diabetes: A single-arm pre-post study.
- Prevalence of liver steatosis and stiffness by transient elastography and serum markers in Japanese early adolescents
- Topical Fluticasone Propionate Versus Fusidic Acid for Zoon’s Balanitis in Men: A Prospective, Open-Label, Non-Randomised Comparative Study with an Exploratory Long-Term Assessment
- Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis
BibTeX
@article{nunezmercado2026prospective,
title = {{Prospective comparative assessment of liver stiffness and steatosis between iLivTouch and FibroScan.}},
author = {Frida Nuñez-Mercado and Eva Juárez-Hernández and Raúl A Gómez-Mendoza and Martha H Ramos-Ostos and Misael Uribe and Graciela Castro-Narro and Iván López-Méndez},
journal = {Hepatology communications},
year = {2026},
month = oct,
doi = {10.1097/hc9.0000000000001066},
url = {https://europepmc.org/article/MED/42900156},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prospective comparative assessment of liver stiffness and steatosis between iLivTouch and FibroScan.
AU - Frida Nuñez-Mercado
AU - Eva Juárez-Hernández
AU - Raúl A Gómez-Mendoza
AU - Martha H Ramos-Ostos
AU - Misael Uribe
AU - Graciela Castro-Narro
AU - Iván López-Méndez
PY - 2026
DA - 2026/10/19
JO - Hepatology communications
DO - 10.1097/hc9.0000000000001066
UR - https://europepmc.org/article/MED/42900156
AB - Background Metabolic dysfunction-associated steatotic liver disease currently represents the leading cause of chronic liver disease worldwide. FibroScan and iLivTouch are 2 devices that employ similar principles to estimate liver steatosis and fibrosis, although few studies have directly compared their results.Aim To evaluate the concordance of 2 transient elastography devices for the estimation of liver steatosis and fibrosis.Methods A prospective study was conducted. Each participant underwent liver elastography with both devices consecutively under standardized conditions. Clinical, anthropometric, and biochemical variables were collected. The diagnostic accuracy of iLivTouch was calculated using FibroScan and noninvasive scores as references.Results A total of 1004 patients were enrolled, with a median body mass index of 25.7 kg/m2 [IQR=23.6-28.7]. Median of attenuation values was 250 dB/m [IQR=214-291] with FibroScan, 262 dB/m [IQR=239-310] with iLivTouch. Median liver stiffness measurements were 4.1 kPa [IQR=3.4-4.8] for FibroScan and 6.2 kPa [IQR=5.5-7.1] for iLivTouch. Bland-Altman analysis revealed mean differences of -19.45±49.62 dB/m for steatosis and -2.43±2.51 kPa for stiffness. Using FibroScan (>269 dB/m) as the reference, iLivTouch ≥244 dB/m demonstrated 90% sensitivity for detecting liver steatosis. The correlation between the FAST scores of the 2 devices was very strong (rho=0.90, p≤0.0001).Conclusion iLivTouch serves as an effective alternative to assess liver fibrosis and steatosis in the general population, including overweight and obese individuals.
SN - 2471-254X
ER -